NasdaqCM - Delayed Quote USD

ASLAN Pharmaceuticals Limited (ASLN)

0.4060 -0.0050 (-1.22%)
At close: May 13 at 4:00 PM EDT

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. Founder, CEO & Executive Director -- -- 1973
Mr. Kiran Kumar Asarpota COO & Head of Finance -- -- 1979
Mr. Ben Goodger General Counsel -- -- 1963
Mr. Stephen Doyle Chief Business Officer -- -- 1973
Dr. Alexandre Kaoukhov M.D. Chief Medical Officer -- -- 1974
Charlie Hsu Investor Relations Director -- -- --
Chi-Chin Wang IR & Corporate Development Director -- -- --

ASLAN Pharmaceuticals Limited

3 Temasek Avenue
Level 18 Centennial Tower
Singapore, 039190
Singapore
65 6817 9598 https://aslanpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
35

Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Corporate Governance

ASLAN Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 09, 2024 - Aug 13, 2024
ASLAN Pharmaceuticals Limited Earnings Call

Related Tickers

TCON TRACON Pharmaceuticals, Inc.
2.0200
+4.66%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.7000
-9.09%
 
TERN Terns Pharmaceuticals, Inc.
5.89
+5.94%
 
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.3201
-5.85%
 
NRXP NRx Pharmaceuticals, Inc.
2.9900
-1.64%
 
EYEN Eyenovia, Inc.
0.8157
+5.76%
 
ADIL Adial Pharmaceuticals, Inc.
1.4450
-3.67%
 
CNTB Connect Biopharma Holdings Limited
1.4500
-3.97%
 
ALZN Alzamend Neuro, Inc.
0.5050
-7.02%
 
RNAZ TransCode Therapeutics, Inc.
0.6162
-56.30%